Uncategorized

Eli Lilly’s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure – Yahoo Finance

Posted on Author Comments Off on Eli Lilly’s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure – Yahoo Finance
  1. Eli Lilly’s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure  Yahoo Finance
  2. Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF  Yahoo Finance
  3. Eli Lilly’s weight-loss drug helps nearly 99% of patients remain diabetes-free  Reuters
  4. SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity  TCTMD
  5. Ozempic could prevent diabetes. Should it be used for that?  The Seattle Times